To examine the effects of ursolic acid (UA) on the treatment of gallbladder cancer (GBC) cells, the following steps were performed: 022305 Versican 0.84
   ITGB2: Fibrinogen beta chain 0.98
   ITGB1: Integrin beta-1 1: intercellular adhesion molecule 0.88199 0.91
   MMP2: matrix metalloproteinase-2 1000: Integrin, alpha 2 1.01
   MMP1: matrix metalloproteinase-1 02: Integrin, alpha 2 1.2
   MMP-9: matrix metalloproteinase 1.31: Platelet/endothelial cell adhesion molecule 1.4
   CD44: cluster of differentiation 1.4
   Hyaluronan synthase 2.4: Hyaluronan synthase 2.4
   CD44: cluster of differentiation 2.5
   ITGA3: Integrin, alpha-3 2.5
   MMP13: matrix metalloproteinase 3.0
   CD44: Cluster of differentiation 3.0
   MMP14: Matrix metalloproteinase 3.1
   ITGA5: Integrin, alpha 5 4.1
   MMP19: Matrix metalloproteinase 5.1
   ^a

   Pathway terms with P<0.05 were considered statistically significant. ICAM1, ITGA1, MMP2 and MMP9, ITGA2, HAS1 and CD44. MMP14 versus genes in control cells.  ITGA5 and MMP10, MMP19, MMP13 and MMP14.
   ^b
   ^bPathway terms with P<0.04068: NF-kappa B signaling pathway 0.0001, MMP2
   hsa05205: Proteoglycans in cancer TNF, MMP9, MMP2, MMP1 0.02
   hsa0410: PI3K-Akt signaling pathway ICAM1, ITGA2, MMP9, ITGA3, MMP1, MMP2, MMP9 0.02
   hsa04514: Focal adhesion ITGA1, MMP1, MMP2, MMP9, ITGA2, FN1 0.2
   hsa04060: Chemokine signaling pathway MMP2, ITGA1, MMP9 0.4
   hsa1: Axon guidance ITGA3, MMP9, MMP1, MMP2 0.04
   hsa200: Axon guidance 0.05
   hsa04610: PI3K-Akt signaling pathway 0.1
   hsa10: MAPK signaling pathway 0.1
   hsa0410: MAPK signaling pathway 0.2
   hsa0420: Cytokine-cytokine receptor interaction 0.2
   hsa04: TNF, ICAM1, MMP9 0.2
   hsa0430: Axon guidance 0.2
   hsa041: PI3K-Akt signaling pathway 0.4
   hsa04: Leukocyte transendothelial migration 0.4
   hsa04: NF-kappa B signaling pathway 4.5
   hsa0412: Axon guidance 5.1
   hsa04: TNF, MMP2, ICAM1 5.3
   hsa041: MAPK signaling pathway 5.5
   hsa: Cytokine-cytokine receptor interaction 0.5
   hsa0: PI3K-Akt signaling pathway 5.6
   hsa0: Chemokine signaling pathway 5.6
   hsa041: Axon guidance 5.6
   hsa: NF-kappa B signaling pathway 6.5
   hsa: Cytokine-cytokine receptor interaction 6.6
   hsa0: Focal adhesion 6.7
   hsa0: PI3K-Akt signaling pathway 6.8
   hsa: MAPK signaling pathway 8.0

---

### Answers:

1. **What tool was used for pathway enrichment analysis?**
   - **DAVID**

2. **Was a tool version number provided?**
   - Not described

3. **What gene set library was queried (eg: GO, KEGG, Reactome or other)?**
   - KEGG

4. **Was a background gene list defined for pathway enrichment analysis?**
   - Not described

5. **What statistical test was used for enrichment analysis?**
   - Not described

6. **Was false discovery rate correction used to control the number of false positives in the pathway enrichment analysis?**
   - Not described

---

**Note**: The pathway enrichment analysis and the corresponding tables are presented in the results section. The methods section does not mention anything about the enrichment analysis.

**Note**: The authors have included some of the gene names and their corresponding fold changes are presented in the result section.

